Traders Purchase Large Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw unusually large options trading on Tuesday. Stock traders bought 1,092 call options on the stock. This represents an increase of 1,606% compared to the average daily volume of 64 call options.

BioCryst Pharmaceuticals stock traded up $0.24 during midday trading on Friday, hitting $8.06. 924,638 shares of the company were exchanged, compared to its average volume of 809,895. The firm has a market cap of $861.21 million, a price-to-earnings ratio of -8.13 and a beta of 1.71. BioCryst Pharmaceuticals has a fifty-two week low of $5.12 and a fifty-two week high of $9.95. The company has a quick ratio of 1.62, a current ratio of 1.65 and a debt-to-equity ratio of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28). The company had revenue of $5.89 million for the quarter, compared to analyst estimates of $2.92 million. BioCryst Pharmaceuticals had a negative return on equity of 175.83% and a negative net margin of 490.25%. Equities analysts expect that BioCryst Pharmaceuticals will post -1.2 EPS for the current year.

In other BioCryst Pharmaceuticals news, CFO Thomas R. Staab II sold 9,000 shares of the business’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $7.75, for a total transaction of $69,750.00. Following the completion of the sale, the chief financial officer now directly owns 140,426 shares in the company, valued at approximately $1,088,301.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Thomas R. Staab II sold 7,750 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $7.30, for a total value of $56,575.00. Following the sale, the chief financial officer now owns 140,426 shares of the company’s stock, valued at $1,025,109.80. The disclosure for this sale can be found here. Insiders sold a total of 24,250 shares of company stock valued at $192,400 over the last quarter. 5.20% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Teachers Advisors LLC grew its stake in BioCryst Pharmaceuticals by 4.1% during the third quarter. Teachers Advisors LLC now owns 294,786 shares of the biotechnology company’s stock worth $2,249,000 after buying an additional 11,682 shares during the last quarter. Paloma Partners Management Co bought a new stake in BioCryst Pharmaceuticals during the fourth quarter worth about $84,000. Bank of New York Mellon Corp grew its stake in BioCryst Pharmaceuticals by 3.1% during the third quarter. Bank of New York Mellon Corp now owns 420,825 shares of the biotechnology company’s stock worth $3,211,000 after buying an additional 12,544 shares during the last quarter. JGP Global Gestao de Recursos Ltda. grew its stake in BioCryst Pharmaceuticals by 8.5% during the first quarter. JGP Global Gestao de Recursos Ltda. now owns 25,742 shares of the biotechnology company’s stock worth $210,000 after buying an additional 2,018 shares during the last quarter. Finally, BlackRock Inc. grew its stake in BioCryst Pharmaceuticals by 13.1% during the third quarter. BlackRock Inc. now owns 8,769,856 shares of the biotechnology company’s stock worth $66,914,000 after buying an additional 1,013,905 shares during the last quarter. Institutional investors and hedge funds own 91.81% of the company’s stock.

BCRX has been the subject of a number of recent research reports. JMP Securities boosted their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company a “market outperform” rating in a research note on Tuesday, April 2nd. Piper Jaffray Companies set a $15.00 price target on BioCryst Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, April 22nd. BidaskClub cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, March 19th. Zacks Investment Research cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, April 15th. Finally, Barclays boosted their price target on BioCryst Pharmaceuticals from $6.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, April 2nd. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $11.91.

TRADEMARK VIOLATION WARNING: This report was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/stock-traders-purchase-high-volume-of-call-options-on-biocryst-pharmaceuticals-bcrx.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Recommended Story: Do Tariffs Work?

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.